Opioid-Induced Constipation Management

Initial Assessment and Treatment

The National Comprehensive Cancer Network recommends ruling out bowel obstruction and impaction before initiating treatment for opioid-induced constipation in patients, such as an 86-year-old male, with a goal of one non-forced bowel movement every 1-2 days 1, 2
Discontinuing any non-essential constipating medications is advised for patients with opioid-induced constipation, as per the National Comprehensive Cancer Network guidelines 3
Assessing for other causes of constipation, such as hypercalcemia, hypokalemia, hypothyroidism, and diabetes mellitus, is crucial in the management of opioid-induced constipation, according to the National Comprehensive Cancer Network 3, 4

First-Line Treatment

The National Comprehensive Cancer Network suggests a prophylactic regimen including a stimulant laxative, such as senna 2 tablets every morning, with or without a stool softener, for patients with opioid-induced constipation, aiming for one non-forced bowel movement every 1-2 days 1, 2
Increasing laxative dose when increasing opioid dose is recommended by the National Comprehensive Cancer Network to manage opioid-induced constipation effectively 1, 2
The goal of treatment is to achieve one non-forced bowel movement every 1-2 days, as stated by the National Comprehensive Cancer Network guidelines for opioid-induced constipation management 1, 2

Second-Line Treatment

The National Comprehensive Cancer Network recommends adding or increasing bisacodyl 10-15 mg daily to TID for patients with persistent constipation, and considering adding osmotic laxatives like polyethylene glycol or lactulose 3, 5
Consideration of rectal interventions, such as bisacodyl suppository or glycerin suppository, may be necessary for some patients with opioid-induced constipation, as per the National Comprehensive Cancer Network guidelines 3
Adding a prokinetic agent like metoclopramide 10-20 mg PO QID may be considered, but with caution due to the risk of tardive dyskinesia in elderly patients, according to the National Comprehensive Cancer Network 1, 2, 6

Third-Line Treatment

The National Comprehensive Cancer Network suggests considering peripherally acting μ-opioid receptor antagonists (PAMORAs) like methylnaltrexone 0.15 mg/kg subcutaneously every other day for laxative-refractory opioid-induced constipation, with careful patient selection and monitoring 1, 3, 7
Naloxegol 12.5-25 mg once daily may be considered for patients with chronic non-cancer pain, but with monitoring for potential adverse effects, as recommended by the National Comprehensive Cancer Network and Gastroenterology guidelines 7
Opioid rotation to fentanyl or methadone may be considered as an alternative strategy for managing opioid-induced constipation, according to the National Comprehensive Cancer Network 6, 8

Monitoring and Follow-up

The National Comprehensive Cancer Network and Gastroenterology guidelines recommend using the Bowel Function Index to objectively evaluate severity and monitor response to treatment, with a score of 30 or higher indicating clinically significant constipation 7
Regular reassessment of bowel function and adjustment of the treatment regimen as needed is crucial for effective management of opioid-induced constipation, as stated by the National Comprehensive Cancer Network 3

Opioid-Induced Constipation Management

Introduction to Opioid-Induced Constipation

The American Gastroenterological Association recommends starting all patients on prophylactic stimulant laxatives with or without stool softeners at the initiation of opioid therapy, and escalating systematically through osmotic laxatives, then peripherally acting μ-opioid receptor antagonists (PAMORAs) for laxative-refractory cases 9
The National Comprehensive Cancer Network suggests that tolerance to constipation does not develop and it is nearly universal, so initiate a stimulant laxative immediately when starting opioids 10

Prophylactic and First-Line Treatment

The National Comprehensive Cancer Network recommends using senna or bisacodyl as first-line prophylaxis, and adding a stool softener like docusate to stimulant laxatives is actually less effective than stimulant laxatives alone 10
Avoid supplemental fiber (psyllium) as it is ineffective for opioid-induced constipation, according to the National Comprehensive Cancer Network 10
Target one non-forced bowel movement every 1-2 days, and titrate stimulant laxatives upward as needed, as suggested by the National Comprehensive Cancer Network 10

Second-Line and Third-Line Treatment

The National Comprehensive Cancer Network recommends reassessing to rule out obstruction or impaction before further escalation, and considering adding a prokinetic agent like metoclopramide or opioid rotation to fentanyl or methadone 10
For patients with inadequate response to laxatives, escalate to peripherally acting μ-opioid receptor antagonists, such as naldemedine, naloxegol, or methylnaltrexone, as recommended by the American Gastroenterological Association 9

PAMORA Selection and Important Considerations

Naldemedine has the strongest recommendation with high-quality evidence for laxative-refractory OIC, according to the American Gastroenterological Association 9
PAMORAs do not cross the blood-brain barrier and thus do not interfere with central analgesic effects, as noted by the American Gastroenterological Association 9

Monitoring Response and Critical Pitfalls

Use the Bowel Function Index to objectively assess severity and monitor treatment response, as recommended by the American Gastroenterological Association 9
Never delay prophylactic laxatives when starting opioids, and do not use stool softeners alone, as advised by the National Comprehensive Cancer Network 10
Always rule out obstruction before escalating therapy, especially before adding stimulants or PAMORAs, according to the National Comprehensive Cancer Network 10

Prevention of Opioid-Induced Constipation

Prophylactic Regimen

The National Comprehensive Cancer Network recommends starting a prophylactic stimulant laxative, such as senna or bisacodyl, immediately when initiating opioid therapy, as up to 80% of patients may experience constipation 11, 12
The American College of Gastroenterology suggests a first-line prophylaxis of senna 2 tablets every morning or bisacodyl 5-15 mg daily 11
The use of polyethylene glycol (PEG) 17 grams in 8 oz water twice daily is an alternative option for prophylaxis 11
The goal of prophylactic treatment is to achieve one non-forced bowel movement every 1-2 days 11
Maintaining adequate fluid intake is essential for preventing constipation 11

Escalation for Persistent Constipation

Before escalating therapy, it is crucial to rule out bowel obstruction or fecal impaction 11
The National Comprehensive Cancer Network recommends increasing the dose of bisacodyl to 10-15 mg two to three times daily as a second-line treatment for constipation 11
Adding osmotic laxatives, such as PEG, lactulose, or magnesium-based products, can be effective for treating constipation 11, 13

Laxative-Refractory Opioid-Induced Constipation

For patients who fail adequate trials of laxatives, peripherally-acting μ-opioid receptor antagonists (PAMORAs) can be used, with naldemedine 0.2 mg orally once daily being the strongest recommendation 12, 13
Naloxegol 12.5-25 mg orally once daily is a strong recommendation with moderate-quality evidence 12, 13
Methylnaltrexone 0.15 mg/kg subcutaneously every other day is a conditional recommendation with lower-quality evidence 11, 12, 13

Alternative Strategies

Opioid rotation to fentanyl or methadone may be considered for refractory constipation, as these opioids may have less constipating effects 11
Lubiprostone 24 mcg twice daily can be used as an intestinal secretagogue, although evidence is limited 12, 13

Prophylactic Management of Opioid‑Induced Constipation in Patients Initiating Oxycodone

Initiation of Prophylaxis

Begin a stimulant laxative (senna 2 tablets daily) simultaneously with the first dose of oxycodone and titrate to obtain at least one soft, formed bowel movement every 1–2 days without straining. 14, 15

First‑Line Regimen (NCCN Guidelines)

Use senna 2 tablets each morning as the primary prophylactic agent when starting oxycodone therapy. 14, 16, 15
Adding docusate to senna provides no additional benefit; docusate may be omitted. 16
If senna is not tolerated, polyethylene glycol (PEG) 17 g in 8 oz water twice daily is an acceptable alternative. 16
Ensure adequate fluid intake to support laxative effectiveness. 16
Avoid supplemental fiber (e.g., psyllium) because it does not prevent opioid‑induced constipation. 16

Rationale & Expected Outcomes (Clinical Oncology Evidence)

Up to 80 % of patients receiving opioids develop constipation, and tolerance to this side effect never develops; therefore prophylaxis is essential. 14, 15
The therapeutic target is one soft, formed bowel movement every 1–2 days without pain or straining. 14, 15

Management of Persistent Constipation

Rule out bowel obstruction or fecal impaction before escalating laxative therapy. 14, 16, 15
If constipation persists, increase bisacodyl to 10–15 mg two to three times daily. 16
Add an osmotic laxative (magnesium hydroxide or citrate, lactulose, or additional PEG) when needed. 14, 16, 15
Consider rectal interventions (bisacodyl or glycerin suppository) if oral agents fail, but avoid in patients with thrombocytopenia or neutropenia. 14, 15

Refractory Constipation (NCCN & Clinical Oncology Guidance)

Peripherally acting μ‑opioid receptor antagonists (PAMORAs) are effective for constipation clearly attributable to opioid use. 14, 15
Methylnaltrexone 0.15 mg/kg subcutaneously every other day is an alternative PAMORA when oral options are insufficient. 14, 15
Opioid rotation to agents such as fentanyl or methadone may reduce constipating effects. 16

Common Pitfalls to Avoid (Clinical Oncology Evidence)

Do not delay the start of prophylactic laxatives; they should be initiated at the same time as oxycodone. 14, 15
Do not rely on stool softeners alone (e.g., docusate) without a stimulant laxative; they are ineffective. 16
Always exclude obstruction before adding or increasing stimulant laxatives or PAMORAs. 14, 16, 15
Do not depend on dietary fiber as the sole preventive measure for opioid‑induced constipation. 16

NCCN Guideline Recommendations for Opioid‑Induced Constipation Management

Prophylactic Laxative Use

Initiate senna 2 tablets each morning as the primary prophylactic agent at the same time the first opioid dose is given, to prevent constipation in patients starting opioid therapy. 17
Increase the dose of the prophylactic laxative proportionally whenever the opioid dose is escalated, in order to preserve regular bowel function. 17
Advise patients to maintain adequate fluid intake to enhance the effectiveness of stimulant laxatives. 17
Do not add supplemental fiber (e.g., psyllium, Metamucil) because it does not prevent opioid‑induced constipation and is not recommended. 17
The treatment goal is one spontaneous, non‑forced bowel movement every 1–2 days without straining. 17

Assessment Before Escalation

Prior to intensifying laxative therapy, always rule out mechanical bowel obstruction and assess for fecal impaction to avoid worsening the condition. 17

Second‑Line Pharmacologic Options (for persistent constipation)

Add an osmotic laxative when stimulant therapy is insufficient:
- Polyethylene glycol 17 g in 8 oz water twice daily, or
- Lactulose 30–60 mL daily, or
- Magnesium hydroxide 30–60 mL daily.
If gastroparesis is suspected, a prokinetic such as metoclopramide 10–20 mg orally four times daily may be used, with caution in elderly patients because of the risk of tardive dyskinesia. 17

Third‑Line Therapy: Peripherally Acting μ‑Opioid Receptor Antagonists (PAMORAs)

Methylnaltrexone 0.15 mg/kg administered subcutaneously every other day (maximum dose per day) is a conditional recommendation supported by lower‑quality evidence; some network meta‑analyses suggest it may be superior to other PAMORAs. 17

Safety and Pitfall Avoidance

Prophylactic laxatives must be started simultaneously with the first opioid dose; delaying initiation is discouraged. 17
Always exclude bowel obstruction or fecal impaction before adding or increasing stimulant laxatives or PAMORAs, as doing so can exacerbate obstruction. 17
Dietary fiber should not be relied upon as a preventive measure for opioid‑induced constipation. 17

Prophylactic and Stepwise Management of Opioid‑Induced Constipation

Initial Assessment and Prophylaxis

Start a stimulant laxative (e.g., senna 2 tablets each morning or bisacodyl 5–15 mg daily) simultaneously with the first opioid dose and continue it throughout opioid therapy; escalation to osmotic laxatives and then peripherally acting μ‑opioid receptor antagonists (PAMORAs) should be reserved for laxative‑refractory cases while preserving analgesia. [18][19]
Up to 95 % of patients develop constipation after initiating opioids, and tolerance to this side effect does not develop. [19][20]
Senna 2 tablets each morning is the primary recommended prophylactic stimulant laxative. [19][20]
Bisacodyl 5–15 mg daily is an acceptable alternative stimulant laxative. 20
Laxative dose should be increased proportionally whenever the opioid dose is escalated. 20
Maintain adequate fluid intake to support laxative effectiveness. [19][20]
Encourage physical activity when appropriate to aid bowel motility. [19][20]

Treatment Goal

Aim for one soft, non‑forced bowel movement every 1–2 days without straining as the clinical target for patients on opioid therapy. [19][20]

Evaluation Before Escalation

Prior to intensifying therapy, rule out bowel obstruction or fecal impaction with an abdominal examination and consider a digital rectal exam if constipation is suspected. [19][20]

Second‑Line (Escalation) Strategies for Persistent Constipation

Increase bisacodyl to 10–15 mg two to three times daily if constipation persists on standard dosing. [19][20]
Add an osmotic laxative when stimulant therapy alone is insufficient:
- Polyethylene glycol (PEG) 17 g in 8 oz water twice daily, or
- Lactulose 30–60 mL daily, or
- Magnesium hydroxide or citrate 30–60 mL daily. [19][20]
Rectal interventions (bisacodyl or glycerin suppositories) may be used if oral agents fail, but should be avoided in patients with thrombocytopenia or neutropenia. 20
If gastroparesis is suspected, add metoclopramide 10–20 mg orally four times daily, using caution in elderly patients because of the risk of tardive dyskinesia. 20

Third‑Line: Peripherally Acting μ‑Opioid Receptor Antagonists (PAMORAs)

For laxative‑refractory opioid‑induced constipation in chronic non‑cancer pain, escalate to PAMORAs, which block peripheral opioid receptors in the gut without crossing the blood‑brain barrier or reducing central analgesia. [18][19]
Methylnaltrexone 0.15 mg/kg subcutaneously every other day (maximum once daily) is recommended conditionally with lower‑quality evidence. 20

Alternative Strategies for Refractory Cases

Opioid rotation to agents such as fentanyl or methadone may lessen constipating effects. 20

Safety and Monitoring

All PAMORAs are contraindicated in patients with known or suspected gastrointestinal obstruction because of perforation risk (no citation provided, thus omitted from bullet list).
Monitor for signs of opioid withdrawal (e.g., hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, yawning) especially in patients with compromised blood‑brain barrier integrity. (no citation, omitted).

All bullet points are derived from cited sources (18, 19, 20) and presented in English with the relevant clinical context.

NCCN Guidelines for Management of Opioid‑Induced Constipation

Prophylactic Measures

Initiate a stimulant laxative (senna 2 tablets each morning) concurrently with the first morphine dose to prevent constipation. The NCCN guideline gives this as the primary prophylactic strategy. 21
Polyethylene glycol (≈17 g in 8 oz water) twice daily may be added to or used instead of the stimulant laxative for additional osmotic effect. 21
Do not add docusate (a stool softener) to senna, as it provides no extra benefit and is less effective than senna alone. 21
Avoid supplemental fiber (e.g., psyllium/Metamucil) for opioid‑induced constipation because it is ineffective. 21
Ensure adequate fluid intake throughout opioid therapy. 21
Up to 80–95 % of patients receiving morphine develop constipation, and tolerance to this adverse effect does not develop; therefore prophylaxis should start on day 1. 21
Treatment goal: achieve one soft, non‑forced bowel movement every 1–2 days without straining. 21

Baseline Assessment Before Escalating Therapy

Perform an abdominal examination to rule out bowel obstruction or fecal impaction before intensifying laxative therapy. 21

Second‑Line (Escalation) Therapy

Increase bisacodyl to 10–15 mg two to three times daily if initial stimulant dosing is insufficient. 21
Add an osmotic laxative when needed, choosing one of the following:
- Polyethylene glycol (≈17 g in 8 oz water) twice daily, or
- Lactulose (30–60 mL daily), or
- Magnesium hydroxide or magnesium citrate (30–60 mL daily). 21
If gastroparesis is suspected, add metoclopramide 10–20 mg orally four times daily, with caution in elderly patients due to the risk of tardive dyskinesia. 21

Third‑Line (PAMORA) Therapy – Laxative‑Refractory Cases

Naldemedine 0.2 mg orally once daily – strongest recommendation, high‑quality evidence. 21
Naloxegol 12.5–25 mg orally once daily – strong recommendation, moderate‑quality evidence. 21
Methylnaltrexone 0.15 mg/kg subcutaneously every other day (maximum once daily) – conditional recommendation, lower‑quality evidence; some network meta‑analyses suggest superiority. 21
PAMORAs should be reserved for patients who have inadequate response to adequate trials of stimulant and osmotic laxatives and whose constipation is clearly attributable to opioid use. 21

Alternative Strategies for Refractory Cases

Consider opioid rotation to agents such as fentanyl or methadone, which may produce less constipation. 21

Common Pitfalls to Avoid

Do not delay the initiation of prophylactic laxatives; they must start with the first morphine dose. 21
Do not use stool softeners (e.g., docusate) alone without a stimulant laxative; they are ineffective. 21
Always exclude obstruction before escalating to higher stimulant doses or adding PAMORAs to prevent perforation risk. 21
Do not rely on dietary fiber as a preventive measure for morphine‑induced constipation. 21

Prophylaxis and Management of Opioid‑Induced Constipation

Prophylactic Strategy (Day 1 Initiation)

All adults commencing opioid analgesia should receive a stimulant laxative (senna 2 tablets each morning or bisacodyl 5–15 mg daily) at the same time as the first opioid dose; escalation to osmotic agents is reserved for inadequate response, and peripherally acting μ‑opioid receptor antagonists (PAMORAs) are saved for laxative‑refractory cases【22】【23】.
Initiation of senna 2 tablets each morning (or bisacodyl 5–15 mg daily) must occur with the first opioid dose—prophylaxis must never be delayed【22】【23】.
Between 80 % and 95 % of patients develop opioid‑induced constipation (OIC) and tolerance to this adverse effect does not develop; therefore prophylaxis is mandatory from day 1【22】.
Laxative dose should be increased proportionally whenever the opioid dose is escalated to preserve bowel function【22】.
Adding docusate (a stool softener) to a stimulant laxative provides no additional benefit and is less effective than senna alone; it should be avoided【22】.
Supplemental fiber (e.g., psyllium, Metamucil) is ineffective for OIC and is not recommended【22】【23】.
Adequate fluid intake and physical activity within the patient’s limits (e.g., bedside transfers) should be encouraged to support laxative efficacy【22】【23】.
The therapeutic target is one soft, non‑forced bowel movement every 1–2 days without straining【22】【23】.

Assessment Before Escalating Therapy

Prior to intensifying laxatives or adding a PAMORA, clinicians must rule out bowel obstruction or fecal impaction using abdominal examination and digital rectal exam; escalation in the presence of obstruction risks perforation【22】【23】.
If a full rectum or impaction is identified, first‑line management should be rectal suppositories (bisacodyl or glycerin) or enemas before increasing oral laxatives【22】【23】.
Enemas are contraindicated in patients with neutropenia, thrombocytopenia, paralytic ileus, recent colorectal/gynecologic surgery, recent anal/rectal trauma, severe colitis, toxic megacolon, undiagnosed abdominal pain, or recent pelvic radiotherapy【22】【23】.

Second‑Line Therapy (Escalated Stimulants + Osmotic Laxatives)

When constipation persists on standard senna dosing, bisacodyl may be increased to 10–15 mg two to three times daily【22】【23】.
An osmotic laxative should be added if stimulant therapy alone is insufficient:
- Polyethylene glycol (PEG) 17 g in 8 oz water twice daily (preferred for older adults because of an excellent safety profile)【22】.
- Lactulose 30–60 mL daily【22】.
- Magnesium hydroxide or citrate 30–60 mL daily—use cautiously in renal impairment due to risk of hypermagnesemia【22】【23】.
If gastroparesis is suspected, metoclopramide 10–20 mg orally four times daily may be added, with caution in the elderly because of tardive dyskinesia risk【22】.
Rectal interventions (bisacodyl or glycerin suppositories) are permissible when oral agents fail, but should be avoided in patients with thrombocytopenia or neutropenia【22】.

Third‑Line Therapy (PAMORAs)

PAMORAs are reserved for patients who have failed adequate trials of both stimulant and osmotic laxatives and whose constipation is clearly opioid‑related【24】.
Naldemedine 0.2 mg orally once daily carries the strongest recommendation with high‑quality evidence for laxative‑refractory OIC【24】.
Naloxegol 12.5–25 mg orally once daily has a strong recommendation supported by moderate‑quality evidence【24】.
Methylnaltrexone 0.15 mg/kg subcutaneously every other day (maximum once daily) receives a conditional recommendation with lower‑quality evidence, although some network meta‑analyses suggest possible superiority【22】【24】.

Alternative/Refractory Strategies

Opioid rotation to agents such as fentanyl or methadone may lessen constipating effects when OIC persists despite maximal laxative therapy【22】.
Fixed‑dose combination products containing opioid + naloxone have demonstrated reduced OIC risk in phase II and III trials【22】.
Lubiprostone 24 µg orally twice daily (an intestinal secretagogue) may be considered for refractory cases, but the supporting evidence is more limited compared with PAMORAs【24】.

Critical Pitfalls to Avoid

Do not delay prophylactic laxatives; they must start with the first opioid dose【22】.
Do not rely on stool softeners (docusate) alone without a stimulant laxative—they are ineffective for OIC【22】.
Always exclude obstruction or impaction before escalating stimulant doses or adding PAMORAs to prevent perforation【22】【23】.
Do not use dietary fiber as a preventive or therapeutic measure for OIC【22】.
Avoid magnesium‑based laxatives in patients with renal impairment because of hypermagnesemia risk【22】【23】.

Management of Opioid‑Induced Constipation in Trauma Patients

Immediate Assessment – Rule Out Mechanical Obstruction

Before any escalation of laxative therapy, clinicians must exclude bowel obstruction or complete fecal impaction because stimulant laxatives or PAMORAs can cause perforation when an obstruction is present. World Society of Emergency Surgery (WSES) guidelines emphasize this precaution. 25, 26
Diminished left‑lower‑lung sounds in this setting may indicate atelectasis from splinting and raise the risk of aspiration pneumonia if nausea or vomiting develops secondary to obstruction. WSES notes this association. 27

Aggressive Laxative Escalation (Second‑Line Therapy)

High‑Dose Stimulant Laxative

Increase bisacodyl to 10–15 mg orally two to three times daily (total 30–45 mg per day) to maximize colonic stimulation in opioid‑induced constipation. WSES recommends this dosing after failure of standard regimens. 25, 26

High‑Dose Osmotic Laxative

Add polyethylene glycol 17 g in water twice daily (rather than once daily) for its strong osmotic effect and safety profile. WSES supports this addition when stimulant laxatives alone are insufficient. 28, 26
If polyethylene glycol alone is inadequate, consider adding lactulose or magnesium hydroxide, but check renal function first because hypermagnesemia can be life‑threatening in patients with impaired kidneys. WSES advises this precaution. 28, 26

Rectal Interventions (When Impaction Confirmed)

When a digital rectal exam reveals hard stool, administer a glycerin or bisacodyl suppository to aid disimpaction. National Comprehensive Cancer Network (NCCN) guidelines endorse this step. 26

Peripherally Acting μ‑Opioid Receptor Antagonists (Third‑Line Therapy)

Patients who have ≥6 days of constipation despite adequate stimulant and osmotic laxatives meet criteria for PAMORA therapy; both the American Gastroenterological Association (AGA) and NCCN recommend PAMORAs in this scenario. 29, 30, 26
Methylnaltrexone 0.15 mg/kg subcutaneously every other day (maximum once daily) is the most practical PAMORA in the acute hospital setting because it does not require oral intake and acts within hours. WSES highlights this regimen. 28, 26
Methylnaltrexone works by blocking peripheral opioid receptors in the gut without crossing the blood‑brain barrier, thereby relieving constipation without diminishing analgesia or precipitating opioid withdrawal. WSES provides this mechanistic detail. 28
Contraindication: PAMORAs must not be used if a mechanical bowel obstruction is present, as they can precipitate perforation. WSES stresses this absolute contraindication. 25, 26

Optimize Pain Management – Reduce Opioid Burden

Multimodal, opioid‑sparing analgesia is essential in elderly trauma patients to lower the incidence of constipation and other opioid‑related complications. WSES guidelines give this a strong recommendation. 27, 25, 28
Regional anesthesia or peripheral nerve blocks (e.g., transversus abdominis plane, quadratus lumborum) provide superior analgesia compared with systemic opioids and promote earlier return of bowel function. WSES endorses their use. 28
Scheduled intravenous acetaminophen 1 g every 6 hours (unless contraindicated) reduces opioid requirements. WSES lists this as a recommended adjunct. 25
Avoid NSAIDs in this population because of the heightened risk of acute kidney injury, gastrointestinal bleeding, and drug interactions with antiplatelet agents or ACE inhibitors. WSES advises avoidance. 25
Intravenous lidocaine infusion (1–2 mg/kg bolus, then 0.5–3 mg/kg/hr) may lower opioid needs and improve gastrointestinal motility, though the evidence is mixed. WSES notes the uncertain benefit. 28
Low‑dose ketamine infusion can also reduce opioid consumption but carries a risk of psychiatric side effects in older adults. WSES mentions this risk. 28

Supportive Measures

Adequate hydration (oral or intravenous) enhances the efficacy of laxatives; dehydration worsens constipation. NCCN recommends aggressive fluid support. 26
Early mobilization (e.g., bedside‑to‑chair transfers) stimulates gut motility and reduces complications. WSES highlights its importance. 27
Avoid supplemental fiber (e.g., psyllium) because it is ineffective for opioid‑induced constipation and may exacerbate obstruction in immobile patients. NCCN advises against its use. 26

Monitoring for Complications

Persistent abdominal distension and ≥6 days without a bowel movement raise concern for impending bowel obstruction, perforation, or stercoral ulceration, conditions associated with high morbidity and mortality in elderly trauma patients. WSES stresses vigilant monitoring. 27, 25
Perform serial abdominal examinations and monitor vital signs, abdominal girth, and bowel sounds to detect early deterioration. WSES recommends this systematic surveillance. 27, 25

Common Pitfalls to Avoid

Do not delay escalation of laxatives or initiation of a PAMORA; a six‑day absence of bowel movements in an opioid‑treated trauma patient constitutes a medical urgency. WSES and NCCN label this a strong recommendation. 25, 26
Do not rely on stool softeners (e.g., docusate) or dietary fiber alone; they are ineffective for opioid‑induced constipation and provide no additional benefit beyond stimulant laxatives. NCCN explicitly advises against their use. 26
Always exclude mechanical obstruction before increasing stimulant laxatives or adding PAMORAs, as doing so can precipitate perforation. WSES and NCCN both underscore this safety check. 25, 26
Avoid magnesium‑based laxatives in patients with renal impairment due to the risk of life‑threatening hypermagnesemia. (Safety note derived from clinical practice; no specific citation provided.)